Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5274920
Max Phase: Preclinical
Molecular Formula: C31H27N7O3
Molecular Weight: 545.60
Associated Items:
ID: ALA5274920
Max Phase: Preclinical
Molecular Formula: C31H27N7O3
Molecular Weight: 545.60
Associated Items:
Canonical SMILES: C=CC(=O)Nc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cncc(NC(=O)[C@@H](N)Cc5ccccc5)c4)cc23)cc1
Standard InChI: InChI=1S/C31H27N7O3/c1-2-28(39)34-23-11-8-20(9-12-23)30(40)36-29-25-16-21(10-13-27(25)37-38-29)22-15-24(18-33-17-22)35-31(41)26(32)14-19-6-4-3-5-7-19/h2-13,15-18,26H,1,14,32H2,(H,34,39)(H,35,41)(H2,36,37,38,40)/t26-/m0/s1
Standard InChI Key: RKKBVXKJICHLRV-SANMLTNESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 545.60 | Molecular Weight (Monoisotopic): 545.2175 | AlogP: 4.51 | #Rotatable Bonds: 9 |
Polar Surface Area: 154.89 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 5 |
#RO5 Violations: 1 | HBA (Lipinski): 10 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.98 | CX Basic pKa: 8.00 | CX LogP: 3.94 | CX LogD: 3.25 |
Aromatic Rings: 5 | Heavy Atoms: 41 | QED Weighted: 0.17 | Np Likeness Score: -0.95 |
1. Yang B, Zhang H, Li N, Gao L, Jiang H, Kan W, Yuan H, Li J, Zhao D, Xiong B, Zhou Y, Guo D, Liu T.. (2022) Discovery of Novel N-(5-(Pyridin-3-yl)-1H-indazol-3-yl)benzamide Derivatives as Potent Cyclin-Dependent Kinase 7 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease., 65 (23.0): [PMID:36384292] [10.1021/acs.jmedchem.2c01334] |
Source(1):